Maze (MAZE) CEO Jason V. Coloma Sells 22,638 Shares

What Happened

• Jason V. Coloma, CEO of Maze Therapeutics (MAZE), sold a total of 22,638 shares in transactions on Sept. 2–3, 2026, receiving roughly $593,955 (~$594K). Individual reported lots: 9,852 shares @ $26.38 ($259,856); 1,375 @ $27.12 ($37,292); 11,282 @ $26.01 ($293,482); and 129 @ $25.77 ($3,325). These were sales (not purchases) and—per the filing—primarily to satisfy tax withholding on vested restricted stock units (RSUs), a routine administrative sale.

Key Details

• Transaction dates: 2026-09-02 and 2026-09-03; filing date: 2026-09-04 (appears timely).
• Prices: weighted-average prices reported; filing footnotes show sale price ranges of $25.743–$26.65, $26.03–$27.00, and $27.055–$27.40 across the multiple executions.
• Reason: Footnote indicates sales were to satisfy tax withholding obligations related to RSU vesting (tax-withholding/cashless sale).
• Holdings after transaction: Not specified in the provided summary of the Form 4.
• Ownership vehicle notes: Some securities are held directly by The Coloma 2021 Irrevocable Trust and the Coloma Family Trust, for which Mr. Coloma and his spouse are co-trustees.
• Additional: The filer offers to provide a per-price breakdown on request (per Form 4 footnotes).

Context

• Sales to cover tax withholding on vested RSUs are common and are generally administrative (do not necessarily reflect a change in an insider’s view of the company).
• These were outright sales (code S), not option exercises or gifts. If you follow insider activity, purchases tend to carry more signaling weight than routine tax-withholding sales.